Vimarsana
Biggest News Aggregation in the World

Page 9 - Neil Kumar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neil Kumar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neil Kumar Today - Breaking & Trending Today

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson Sells 24,424 Shares - Vimarsana News

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson Sells 24,424 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CFO Brian C. Stephenson sold 24,424 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $14.01, for a total transaction of $342,180.24. Following the sale, the chief financial officer now owns 36,408 shares in the company, […]

Source: wkrb13.com
Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells 51,552 Shares of Stock - Vimarsana News

Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells 51,552 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CEO Neil Kumar sold 51,552 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $14.01, for a total transaction of $722,243.52. Following the completion of the sale, the chief executive officer now directly owns […]

Contrasting Aptorum Group (NASDAQ:APM) & BridgeBio Pharma (NASDAQ:BBIO) - Vimarsana News

Contrasting Aptorum Group (NASDAQ:APM) & BridgeBio Pharma (NASDAQ:BBIO)

Aptorum Group (NASDAQ:APM – Get Rating) and BridgeBio Pharma (NASDAQ:BBIO – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Aptorum Group and BridgeBio Pharma’s net […]

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $29.00 - Vimarsana News

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $29.00

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) had its price target boosted by Mizuho from $23.00 to $29.00 in a research note issued to investors on Monday, The Fly reports. A number of other equities research analysts have also recently commented on BBIO. The Goldman Sachs Group raised their price target on BridgeBio Pharma from $20.00 […]

Mizuho Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $29.00 - Vimarsana News

Mizuho Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $29.00

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) had its target price boosted by Mizuho from $23.00 to $29.00 in a report released on Monday, The Fly reports. A number of other analysts have also issued reports on the company. The Goldman Sachs Group raised their price target on BridgeBio Pharma from $20.00 to $28.00 and gave […]